Navigation Links
Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients

STOCKHOLM, August 20, 2013 /PRNewswire/ --

Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).


The trial is an open-label Phase II study designed to determine the level of efficacy of melflufen in combination with dexamethasone, for late stage, relapsing or relapsing/refractory patients. The primary end point is, best response in accordance with the International Myeloma Working Group criteria during up to eight cycles of treatment.

The trial is being carried out across four centers in Europe (the Netherlands, Italy, Denmark and Sweden) and two in the USA.

Chief Medical Officer Dr Johan Harmenberg commented, "Cytotoxic compounds form an integral part of combination treatment in malignant disease. Melphalan is part of the standard of care in multiple myeloma and improving this component with melflufen should result in significant patient benefit."

Multiple myeloma is the second most common hematological cancer and manifests from an abnormality of plasma cells, usually in the bone marrow. Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually (International Agency for Research on Cancer).

About Oncopeptides AB

Oncopeptides is a clinical stage pharmaceutical development company working to enhance oncology therapies, by creating cytosuperiors of existing basic cytotoxic compounds.

Oncopeptides is targeting multiple myeloma as a first indication with its lead compound, named melflufen which is a cytosuperior of the chemotherapeutic alkylator melphalan.

A family of enzymes that is overexpressed at very high levels in cancer cells, such as multiple myeloma cells, cleaves melflufen so its active metabolite is entrapped at high concentrations within the diseased cells. This results in partially targeted delivery of the chemotherapeutic compound to the cancer cells, and thereby better treatment of the disease.

Primary cancer cells from patients representing twenty different types of cancers have been studied, including multiple myeloma, with melflufen showing 50- to 100-fold higher anti-tumor potency over melphalan.

For further information please contact:

Jakob Lindberg CEO
Tel: +46(0)705-695-471


SOURCE Oncopeptides AB
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
2. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
3. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
4. Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
5. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
7. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
8. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
9. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing ... AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
Breaking Biology Technology:
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
Breaking Biology News(10 mins):